Morning Read: Acquisition rumors for Onyx, funds for aging in place and birth control from Colbert

Investors decided that Onyx Pharma was the mystery company that Bayer is rumored to be buying and bid up the company’s share price 8.5% yesterday. The San Francisco company partnered with Bayer on Nexavar and has a stake in promising late-stage cancer drugs.

The Army is changing its approach to post traumatic stress disorder by refining the classic diagnosis and moving away from anti-anxiety and antipsychotic medications. Charles Hoge of the Walter Reed Army Institute of Research said that PTSD should no longer be summarily ruled out if a soldier meets most of the definitions but fails to exhibit classic signs of fear or helplessness, he said. The new policy also says faking PTSD is not something doctors see often.

The American Hospital Association is not impressed with the new proposed payment rule from CMS. The AHA says the CMS used outdated data and a flawed methodology to implement coding cuts included in the rule. (free subscription required)

Independa is getting lots of support from investors for its aging-in-place technology. The firm increased its latest round of funding at $2.35 million. The company’s main product is Angela, a tablet-based application that helps elderly patients stay in their homes rather than move to assisted living or nursing homes.

Stephen Colbert announced two new exciting products from Prescott Pharmaceuticals last night:  weight loss for women and birth control for men. Whether you’re interested in replacing your digestive system with a very long feeding tube or using scorpions to prevent procreation, Prescott has a solution for you.

Veronica Combs

I was the editor in chief at I started writing and editing in the print world and joined a dotcom right before the 2000 crash. I was at TechRepublic/CNET/BNET for 7 years. Health was more interesting to me than the latest version of Windows, so I left for a startup tracking prescription drug news. A year later, MedTrackAlert was acquired by HealthCentral, so I shifted to audience research. The fun of daily news and interviewing smart people brought me to MedCity News in February 2012. More posts by Author

No comments